Latest news with #Glucagon
Business Standard
11-08-2025
- Health
- Business Standard
Lupin launches Glucagon for Injection USP, 1mg/vial in US market
Lupin today announced the launch of Glucagon for Injection USP, 1mg/vial packaged in an emergency kit in the United States. Glucagon for Injection USP, 1mg/vial packaged in an emergency kit is bioequivalent to Glucagon for Injection, 1 mg/vial of Eli Lilly and Company. Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients. Glucagon for Injection USP, 1mg/vial packaged in an emergency kit had an estimated annual sale of USD 122 million in the U.S. (IQVIA MAT June 2025).
News18
11-08-2025
- Health
- News18
Lupin launches generic medication in US
Agency: PTI Last Updated: New Delhi, Aug 11 (PTI) Drug maker Lupin on Monday said it has launched a medication, used to regulate blood glucose levels, in the US market. The company has launched Glucagon for Injection USP, 1mg/vial packaged in an emergency kit in the US, the Mumbai-based drug maker said in a statement. The company's product is bioequivalent to Eli Lilly and company's Glucagon for Injection, 1 mg/vial, it added. Glucagon is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients. As per IQVIA MAT June data, Glucagon for Injection USP, 1mg/vial packaged in an emergency kit had an estimated annual sale of USD 122 million in the US. PTI MSS DRR DRR First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Business Upturn
11-08-2025
- Health
- Business Upturn
Lupin launches Glucagon for Injection in the U.S. market
By Aditya Bhagchandani Published on August 11, 2025, 10:30 IST Global pharmaceutical major Lupin Limited has announced the launch of Glucagon for Injection USP, 1mg/vial packaged in an emergency kit, in the United States. The product is bioequivalent to Eli Lilly's Glucagon for Injection, 1mg/vial. Glucagon is indicated for treating severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid during radiologic examinations to temporarily inhibit gastrointestinal tract movement in adults. According to IQVIA MAT June 2025 data, Glucagon for Injection USP, 1mg/vial packaged in an emergency kit recorded estimated annual U.S. sales of USD 122 million. Lupin, headquartered in Mumbai, operates in over 100 markets with a strong presence in India and the U.S. across multiple therapy areas. The company runs 15 manufacturing sites and seven research centers globally, supported by over 23,000 employees. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
The Hindu
24-07-2025
- Business
- The Hindu
Lupin gets U.S. FDA nod for two generic diabetes drugs
Generic drugmaker Lupin has received U.S. Food and Drug Administration approval for its abbreviated new drug applications for Liraglutide Injection single-patient-use prefilled pens and Glucagon for injection vials. Both the products will be manufactured at the company's injectable facility in Nagpur, Lupin said. Liraglutide injection 18 mg/3 mL (6 mg/mL) single-patient-use prefilled pen is bioequivalent to Novo Nordisk's Victoza injection and had an estimated annual sale of $458 million in the U.S, the company said citing IQVIA MAT May numbers. The drug is indicated to improve glycaemic control in adults and children, aged above 10 years, with type 2 diabetes mellitus. Glucagon for Injection USP, 1 mg/vial, is bioequivalent to Eli Lilly and Company's Glucagon for Injection, 1 mg/vial. It is indicated for treatment of severe hypoglycaemia in paediatric and adult patients with diabetes mellitus and as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients. It had an estimated annual sale of $124 million in the U.S. Chief Scientific Officer Shahin Fesharaki said the two products are a meaningful enhancement to the company's portfolio.
